Xtrackers SandP MidCap 400 Scored and Screened ETF (MIDE)
Live price chart, market sentiment, and community perspectives for Xtrackers SandP MidCap 400 Scored and Screened ETF (AMEX: MIDE).
Live price chart, market sentiment, and community perspectives for Xtrackers SandP MidCap 400 Scored and Screened ETF (AMEX: MIDE).
Secondary debt liquidity for MIDE proxies remains highly resilient despite headline noise. Watching gross margin expansion.
On our desk, we are monitoring MIDE's mid-channel oscillation pattern very closely. With the price hovering around the $37.85 mark, our quantitative models point toward a neutral near-term outlook that could easily transition into a long-term positive bias if current support holds. We are keeping position sizing tight given the modest market capitalization of roughly $3.41 million.
As a risk manager reviewing our small-cap and mid-cap equity allocations, I notice that short interest in MIDE dropped by 68.1% down to just 838 shares recently. With a days-to-cover ratio at 0.7 days and only 0.9% of shares sold short, immediate short-squeeze potential is virtually absent, leaving performance tethered purely to index performance and underlying macroeconomic factors.
In our quantitative research protocols, evaluating MIDE involves tracking the SandP MidCap 400 Scored and Screened Index alignment. The fund maintains a gross expense ratio of 0.15%, translating to a modest $16 annual cost on a $10,000 investment based on the latest annual shareholder reports. This low friction cost is a vital metric when building long-term allocation models.
From a hedge fund PM perspective, the technical setups generated by AI models for MIDE highlight multiple risk-reward zones, including potential short setups targeting a small percentage of downside versus minimal risk. However, because average daily trading volumes remain relatively light around 587 shares, execution must be handled carefully to avoid slippage.
Looking at the fundamental and technical metrics from Morningstar and Danelfin AI, MIDE trades with a price-to-earnings ratio of 17.76 and a 50-day moving average near $37.56. The 52-week range spans from a low of $30.32 up to $38.46, indicating that the ETF is currently trading near the upper bound of its annual range.
Explore plasma cleansing, somatic organ swaps, and BCI.